Efficacy and Safety Study of Miconazole Lauriad to Treat Oropharyngeal Candidiasis in HIV Patients
This study has been completed.
Sponsor:
BioAlliance Pharma SA
Information provided by:
BioAlliance Pharma SA
ClinicalTrials.gov Identifier:
NCT00390780
First received: October 19, 2006
Last updated: January 9, 2009
Last verified: January 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate the clinical cure of miconazole Lauriad 50 mg (1x50mg) Bioadhesive buccal tablets compared with clotrimazole troches (5x10mg) after 14 days of treatment (at the test of cure visit, at Day 17-19).
Condition | Intervention | Phase |
---|---|---|
HIV Infections |
Drug: miconazole Lauriad |
Phase 3 |
Study Type: | Interventional |
Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
Official Title: | A Comparative Randomized, Double-Blind, Double-Dummy, Multicenter Study of the Efficacy and Safety of Miconazole Lauriad 50mg Administered Once a Day and Mycelex Troches (Clotrimazole 10mg) Administered Five Times a Day in the Treatment of Oropharyngeal Candidiasis in Immunocompromised Patients |
Resource links provided by NLM:
Further study details as provided by BioAlliance Pharma SA:
Primary Outcome Measures:
- Clinical cure (defined as a complete resolution of signs and symptoms) after 14 days of treatment at the Test of Cure visit (Day 17-Day 19) using the scoring scale of Murray
Secondary Outcome Measures:
- Clinical cure at Day 7
- Clinical success rates at Day 7 and at the Test of Cure visit (Day 17-19)
- Microbiological cure at the Test of Cure visit (Day 17-19)
- Rate of relapse at Day 35-38
- General and local tolerability and oral discomfort
- Duration of adhesion of miconazole Lauriad 50 mg bioadhesive buccal tablet
- Systemic exposure of miconazole Lauriad 50 mg bioadhesive buccal tablet
- Susceptibility of Candida species by microdilution test
- Compliance
Enrollment: | 578 |
Study Start Date: | July 2006 |
Study Completion Date: | January 2008 |
Primary Completion Date: | December 2007 (Final data collection date for primary outcome measure) |
Eligibility
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patients with clinical picture of oropharyngeal candidiasis
- Confirmation of oropharyngeal candidiasis by candida culture positive
- HIV-positive patients
- Patients 18 years of age
Exclusion Criteria:
- Patients with signs or symptoms of systemic candidiasis
- Patients with signs or symptoms of esophagitis
- Pregnant or breast-feeding women
- Patients who have taken systemic antifungals within the past 30 days
- Patients who have taken local antifungals within the past 7 days
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00390780
Show 27 Study Locations
Show 27 Study Locations
Sponsors and Collaborators
BioAlliance Pharma SA
More Information
No publications provided
Keywords provided by BioAlliance Pharma SA:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 10, 2013
No publications provided
ClinicalTrials.gov Identifier: | NCT00390780 History of Changes |
Other Study ID Numbers: | BA/2004/01/04 |
Study First Received: | October 19, 2006 |
Last Updated: | January 9, 2009 |
Health Authority: | United States: Food and Drug Administration |
Keywords provided by BioAlliance Pharma SA:
Miconazole Lauriad Oropharyngeal candidiasis HIV patients Mycology |
Clinical picture of Oropharyngeal candidiasis Candida culture positive Treatment Experienced |
Additional relevant MeSH terms:
HIV Infections Acquired Immunodeficiency Syndrome Candidiasis Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases |
Mycoses Miconazole Clotrimazole Antifungal Agents Anti-Infective Agents Therapeutic Uses Pharmacologic Actions 14-alpha Demethylase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Infective Agents, Local |
ClinicalTrials.gov processed this record on March 10, 2013